Furthermore, a study by Carter et al. demonstrated that the inhibition of MCL-1 sensitizes AML cells and AML stem/progenitor cells to BCL-2 inhibition, including those with intrinsic and acquired resistance to venetoclax. The gene discussed is BCL2; the disease is acute myeloid leukemia.